SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 58 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $1,787,000 | +16.6% | 150,000 | 0.0% | 0.07% | +3.1% |
| Q2 2018 | $1,532,000 | -21.3% | 150,000 | 0.0% | 0.06% | -29.7% |
| Q1 2018 | $1,947,000 | +33.4% | 150,000 | 0.0% | 0.09% | +19.7% |
| Q4 2017 | $1,460,000 | -33.9% | 150,000 | 0.0% | 0.08% | -39.2% |
| Q3 2017 | $2,208,000 | -8.5% | 150,000 | 0.0% | 0.12% | -16.7% |
| Q2 2017 | $2,414,000 | +1.0% | 150,000 | 0.0% | 0.15% | -5.1% |
| Q1 2017 | $2,390,000 | +31.0% | 150,000 | 0.0% | 0.16% | +32.8% |
| Q4 2016 | $1,824,000 | -12.3% | 150,000 | 0.0% | 0.12% | -6.3% |
| Q3 2016 | $2,081,000 | -23.6% | 150,000 | 0.0% | 0.13% | -24.0% |
| Q2 2016 | $2,723,000 | – | 150,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |